µ²ºc¦¡ |
|
Tocilizumab¬°¤@ºØ¤HÃþ¤Æ«²Õ§Ü¤HÃþ¤¶¥Õ¯À-6 (IL-6)¨üÅ餧³æ®è§ÜÅé¡AÄݧK¬Ì²y³J¥ÕIgG1£e¨È«¬¡A±a¦³¨å«¬ªºH2L2¦h肽µ²ºc¡C¨C¤@»´Ãì¤Î«Ãì¬Ò¦U¥Ñ214¤Î448ÓÓi°ò»Ä¤À¤l²Õ¦¨¡C¥|Ó¦h肽Ã쪺¤À¤l¤º¤Î¤À¤l¶¡³sµ²¥ÑÂù²¸Áä²Õ¦¨¡A¥Dn¦¨¤Àªº¤À¤l¶q¬ù¬°148 kDa¡C¦¹§ÜÅé«Y©ó÷¨ÅÃþ°Êª«(¤¤°êܹ«§Z±_)²ÓM¤¤»s³y¦Ó±o¡C
|
UpToDate |
UpToDate ³sµ²
|
ÃIJz§@¥Î |
|
Tocilizumab¥i»P¥i·»©Ê¤Î´Oªþ©ó½¤¤Wªº¨âºØIL-6±µ¨üÅé(sIL-6R¤ÎmIL-6R)¶i¦æµ²¦X¡A¨ÃÅã¥Ü¥i§í¨îIL-6Âǥѳo¨Ç¨üÅé©Ò½Õ¸`ªº°T¸¹¶Ç»¼¡CIL-6¬°¤@ºØ¦h®Ä«Pµoª¢²ÓM¿E¯À¡A¥ÑT²ÓM¡BB²ÓM¡B²O¤Ú²y¡B³æ®Ö²y¤ÎÅÖºû¥À²ÓMÄÀ¥X¡CIL-6¤wÃÒ¹ê»PT²ÓM¬¡¤Æ¡B«P¶i§K¬Ì²y³J¥Õ¤Àªc¡B±Ò°Ê«æ©Ê´Á¤§¨xŦ³J¥Õ½è¦X¦¨¡A¥H¤Î¨ë¿E³y¦å«eÅX²ÓM¼W¥Í»P¤À¤Æµ¥¦hºØ¥Í²z¤ÏÀ³¦³Ãö¡C¦bÃþ·Àã©ÊÃö¸`ª¢µ¥µoª¢¤ÏÀ³¤¤¡A§½³¡·ÆÅn¤Îªí¥Ö²ÓM©Ò¤ÀªcªºIL-6±N¤Þµo§½³¡Ãö¸`¶i¤@¨BÄÀ¥XIL-6¡C
|
¾AÀ³¯g |
|
1. Ãþ·Àã©ÊÃö¸`ª¢(RA) ¦X¨Ömethotrexate (MTX)¥Î©óªvÀø¦¨¦~¤H¤¤«×¦Ü««×Ãþ·Àã©ÊÃö¸`ª¢¡A´¿¨Ï¥Î¤@ºØ©Î¤@ºØ¥H¤W¤§DMARDÃĪ«ªvÀø©Î¸~½FÃa¦º¦]¤l«ú§Ü¾¯(TNF antagonist)ªvÀø¦Ó¤ÏÀ³¤£¨Î©ÎµLªk@¨üªº¯f¤H¡C¦b³o¨Ç¯f¤H¤¤¡AY¯f¤H¹ïMTXµLªk@¨ü©Î¤£¾A¦XÄ~Äò§ë»PMTX¡A¥iµ¹¤©¥»«~³æ¿WªvÀø¡C·í»PMTX¦X¨Ö¨Ï¥Î®É¡A¸gX¥ú量´ú¡A¥i´î½wÃö¸`¶Ë®`惡¤Æ³t度¡A¦¹¥~¡A¸gHAQ-DI量ªíµû¦ô¡A¥i§ïµ½¥Í理¥\¯à¡C 2. Ãþ·Àã©ÊÃö¸`ª¢(RA) ¡V ¥¼´¿¨Ï¥ÎMTXªvÀøªºRA ¦X¨Ömethotrexate (MTX)¾A¥Î©óªvÀø¥ý«e¥¼´¿¨Ï¥ÎMTXªvÀøªº««×¡B¬¡°Ê©Ê¡B¶i¦æ©ÊÃþ·Àã©ÊÃö¸`ª¢¦¨¤H¯f¤H¡C¦b³o¨Ç¯f¤H¤¤¡AY¯f¤H¹ïMTXµLªk@¨ü©Î¤£¾A¦XÄ~Äò§ë»PMTX¡A¥iµ¹¤©¥»«~³æ¿WªvÀø¡C·í»PMTX¦X¨Ö¨Ï¥Î®É¡A¸gX¥ú¶q´ú¡A¥i´î½wÃö¸`¶Ë®`´c¤Æ³t«×¡C 3.¦hÃö¸`©Ê¥®¦~«¬ìµo©ÊÃö¸`ª¢(PJIA) »Pmethotrexate (MTX)¨Ö¥Î¡A¾A¥Î©óªvÀø2·³¥H¤Wªº¬¡°Ê©Ê¦hÃö¸`©Ê¥®¦~«¬ìµo©ÊÃö¸`ª¢¡A¥B¹ïMTXªvÀø¤ÏÀ³¤£¨ÎªÌ¡C¹ï©óµLªk@¨ü©Î¤£¾A¦XÄ~ÄòMTXªvÀøªº¯f¤H¡A¥i³æ¿W¨Ï¥Î¥»«~¡C 4.¥þ¨©Ê¥®¦~«¬ìµo©ÊÃö¸`ª¢(SJIA) ¾A¥Î©óªvÀø2·³¥H¤Wªº¬¡°Ê©Ê¥þ¨©Ê¥®¦~«¬ìµo©ÊÃö¸`ª¢¯f¤H¡A¥B¹ïNSAID¤ÎÃþ©T¾JªvÀø¤ÏÀ³¤£¨Î©ÎµLªk@¨üªÌ¡C 5. ²ÓM¿E¯ÀÄÀ©ñ¯gÔ¸s(CRS) ¾A¥Î©óªvÀø´O¦X§Üì¨üÅé(CAR) T²ÓM»¤µo¤§««×©Î¦M¤Î¥Í©R²ÓM¿E¯ÀÄÀ©ñ¯gÔ¸sªº¦¨¤H¤Î2·³¥H¤W¨àµ£¯f¤H¡C
|
¥Îªk¥Î¶q |
|
Ãþ·Àã©ÊÃö¸`ª¢ Actemra¥i³æ¿Wµ¹ÃÄ¡A©Î»Pmethotrexate¦X¨Ö¨Ï¥Î¡C¦¨¤Hªº«Øij¾¯¶q¬°¨C4¶gµ¹ÃĤ@¦¸¡A¥H60¤ÀÄÁ³æ¦¸ÀR¯ßºwª`§ë¤©¡A°_©l¾¯¶q¬°4 mg/kg¡AµM«áµøÁ{§É¤ÏÀ³½Õ¾ã¬°8 mg/kg¡C ¦hÃö¸`©Ê¥®¦~«¬ìµo©ÊÃö¸`ª¢ Actemra ¥i³æ¿W¨Ï¥Î¡A¥ç¥i»Pmethotrexate¦X¨Ö¨Ï¥Î¡C¹ïPJIA¯f¤H¨C4¶g¤@¦¸¡A¥H60¤ÀÄÁ³æ¦¸ÀR¯ßºwª`¤§¤è¦¡¨Ï¥ÎActemraªvÀø®Éªº«Øij¾¯¶q¬°¡GÅ髧C©ó30¤½¤çªº¯f¤H¡APJIA¯f¤H¨C4¶g¤@¦¸ÀR¯ßµ¹ÃĤ§«Øij¾¯¶q 10 mg/kg Å髹F30¤½¤ç¥H¤Wªº¯f¤H¡APJIA¯f¤H¨C4¶g¤@¦¸ÀR¯ßµ¹ÃĤ§«Øij¾¯¶q 8 mg/kg ¡C ¥þ¨©Ê¥®¦~«¬ìµo©ÊÃö¸`ª¢ Actemra®¥i³æ¿W¨Ï¥Î¡A¥ç¥i»Pmethotrexate¦X¨Ö¨Ï¥Î¡C¹ïSJIA¯f¤H¨C2¶g¤@¦¸¥H60¤ÀÄÁ³æ¦¸ÀR¯ßºwª`¤§¤è¦¡¨Ï¥ÎActemra®ªvÀø®Éªº«Øij¾¯¶q¬°¡G Å髧C©ó30¤½¤çªº¯f¤H¡ASJIA¯f¤H¨C2¶g¤@¦¸ÀR¯ßµ¹ÃĤ§«Øij¾¯¶q 12 mg/kg Å髹F30¤½¤ç¥H¤Wªº¯f¤H¡ASJIA¯f¤H¨C2¶g¤@¦¸ÀR¯ßµ¹ÃĤ§«Øij¾¯¶q 8 mg/kg¡C ²ÓM¿E¯ÀÄÀ©ñ¯gÔ¸s(CRS) ¥Î©óªvÀøCRS®É¡A¶È¥i±Ä¥ÎÀR¯ß³~®|µ¹ÃÄ¡C¹ïCRS¯f¤H¥H60¤ÀÄÁÀR¯ß¿éª`¤§¤è¦¡¨Ï¥ÎActemra®ªvÀø®Éªº«Øij¾¯¶q¬°¡G Å髧C©ó30¤½¤çªº¯f¤H¡ACRS¯f¤HÀR¯ßµ¹ÃĤ§«Øij¾¯¶q 12 mg/kg Å髹F30¤½¤ç¥H¤Wªº¯f¤H¡ACRS¯f¤HÀR¯ßµ¹ÃĤ§«Øij¾¯¶q 8 mg/kg ³æ¿W¨Ï¥Î©Î»P¥Ö½èÃþ©T¾J¦X¨Ö¨Ï¥Î
|
ÃİʤO¾Ç |
|
¸Ô¨£¥é³æ!
|
°Æ§@¥Î |
|
¤W©I§l¹D·P¬V¡B»ó«|ª¢¡BÀYµh¡B°ª¦åÀ£¡BALT¼ÆȤW¤É¡C
|
¥æ¤¬§@¥Î |
|
1.¥Î¥HªvÀø¦¨¤H¾AÀ³¯gªº¨Ö¥ÎÃĪ« ¦bÃþ·Àã©ÊÃö¸`ª¢¯f¤Hªº±Ú¸sÃĪ«°Ê¤O¾Ç¤ÀªR¤¤¡A¨Ã¥¼µo²{tocilizumabªº²M°£²v¨ü¨ìmethotrexate (MTX)¡B«DÃþ©T¾J§Üµoª¢ÃĪ«©Î¥Ö½èÃþ©T¾JÃþÃĪ«¼vÅT¡C ¨Ï¥Î³æ¾¯ÀR¯ß¿éª`Actemra® 10 mg/kg¦X¨Ö¨C¶g¤@¦¸ªºMTX 10-25 mg¡A¹ï©óMTXªºÃĪ«¼ÉÅS¶q¤£·|³y¦¨¨ãÁ{§ÉÅãµÛ©Êªº¼vÅT¡C Actemra®»P¥Íª«©Ê¯e¯f×¹¢§Ü·ÀãÃĪ«(¦pTNF«ú§Ü¾¯µ¥)¨Ö¥Îªºµ²ªG¤´«Ý¬ã¨s[½Ð°Ñ¨£¾¯¶q»Pµ¹ÃĤèªk(2.1)]¡C 2.»PCYP P450¨ü½è¤§¥æ¤¬§@¥Î ¨xŦ¤ºªºCytochrome P450¬¡©Ê·|¨ü¨ì·P¬V¤Îµoª¢©Ê¨ë¿E(¨Ò¦pIL-6µ¥²ÓM¿E¯À)¼vÅT¦Ó¬¡©Ê¤U°¡C¦bÃþ·Àã©ÊÃö¸`ª¢¯f¤H¡Atocilizumab¥iÂǥѧí¨îIL-6ªº°T¸¹¶Ç»¼¡A¦^´_CYP450ªº¬¡©Ê¡A¶i¦Ó¼W¥[¤FCYP450¨ü½èÃþÃĪ«ªº¥NÁ¡CÅé¥~¸ÕÅçÅã¥Ütocilizumab¥i¯à·|¼vÅT¦hºØCYP»Ã¯À(CYP1A2¡BCYP2B6¡BCYP2C9¡BCYP2C19¡BCYP2D6¤ÎCYP3A4)ªí²{¡A¦ý¹ï©óCYP2C8©Î¹B¿é³J¥Õªº¼vÅT¤´¥¼ª¾¡C¦bOmeprazole (¥ÑCYP2C19¤ÎCYP3A4¥NÁÂ)¤Îsimvastatin (¥ÑCYP3A4¥NÁÂ)ªºÅ餺¸ÕÅ礤¡A¦bµ¹¤©³æ¾¯Actemra¤@¶g«áÃĪ«¼ÉÅS¶q¤À§O°§C28%¤Î57%¡CTocilizumabªº¨Ï¥Î¹ï©ó¨º¨Ç¸gCYP450¥NÁÂ¥BªvÀø«ü¼Æ¯U¯¶ªºÃĪ«¥i¯à¦³Á{§ÉÅãµÛªº¼vÅT¡A¦]¦¹¦¹ÃþÃĪ«¤§¾¯¶q»ÝÀH¦U¤H½Õ¾ã¡C¨Ï¥Î¥H¤WÃþ«¬ÃĪ«ªº¯f¤H©ó¶}©l©Î¤¤Â_ActemraÀøµ{®É¡AÀ³¹ïÃĪ«Àø®Ä(¨Ò¦pwarfarin)©ÎÃĪ«¿@«×(¨Ò¦pcyclosporine©Îtheophylline)¶i¦æºÊ´ú¡A¨Ã©ó¥²n®É¹ï¦U§OÃĪ«¾¯¶q¶i¦æ½Õ¾ã¡CÂå®v¶}¥ß³B¤è®É¡AÀ³ª`·NActemra»PCYP3A4¨ü½èÃĪ«(¤fªAÁ×¥¥ÃÄ¡Blovastatin©Îatorvastatinµ¥)¨Ö¥Î¥i¯à·|¤Þ°_ÃĮݧCªº«D¹w´Á¼vÅT¡F§Y¨Ï°±¤î¥ÎÃÄ¡Atocilizumab¹ï©óCYP450ªº»Ã¯À¬¡©Ê¼vÅT¤´¥i«ùÄò¼Æ¶g¡C 3.¬¡©Ê¬Ì] ¥¿¦b¨Ï¥ÎActemraªvÀøªÌ¤£±o±µ¨ü¬¡©Ê¬Ì]¡C
|
¸T§Ò |
|
¸T¥Î©ó¤wª¾¹ïActemra¹L±Ó¯f¤H¡C
|
µ¹¥I³W©w |
|
8.2.4.12.Tocilizumab(¦pActemra)¡G(113/1/1) 1. ¥Î©ó·s«¬«aª¬¯f¬r¯e¯f¡A»Ý¦P®É²Å¦X¤Uz©Ò¦³±ø¥ó¡G (1)¦í°|¦¨¦~¯f¤H¡C (2)»Pdexamethasone¦X¨Ö¨Ï¥Î©óÄY«ªÍª¢¥H¤W(¥¼¨Ï¥Î§l®ñªvÀø¤USpO2 ¡Ø94%¡F»Ý¨Ï¥Î§l®ñªvÀø¡B°ª¬y¶q®ñ®ð©Î«D«Iŧ©Ê©I§l¾¹¡B¨Ï¥Î¾÷±ñ¦¡©I§l¾¹©Î¨Ï¥ÎÅé¥~½¤®ñ¦X¾¹¸§J½¤/ECMO)¤§±wªÌ¡C©Î»Pdexamethasone¤Îremdesivir¦X¨Ö¥Î©ó¥¼¨Ï¥Î§l®ñªvÀø¤USpO2¡Ø 94%¡B»Ý¨Ï¥Î§l®ñªvÀø¡B°ª¬y¶q®ñ®ð©Î«D«Iŧ©Ê©I§l¾¹¤§±wªÌ¡C 2.¾¯¶q8mg/kg¡A³æ¦¸ÀR¯ßª`®g¡A³Ì¤j¾¯¶q800mg¡C
|
ª`·N¨Æ¶µ |
|
ÀR¯ß¿éª`¥ÎªºActemraÀ³¥ÑÂåÃıM·~¤H¤h¥HµLµß¾Þ§@§Þ³N¶i¦æµ}ÄÀ¡A¾Þ§@¨BÆJ¦p¤U¡G ¨Ï¥ÎµLµß°wÀY©Mª`®g¾¹»s³ÆActemra¡C Å髧C©ó30¤½¤çªº¯f¤H¡G¨Ï¥Î¸Ë¦³0.9%©Î0.45%´â¤Æ¶uª`®g¾¯50 mLªº¿éª`³U©Î¿éª`²~¡AµM«á¿í·Ó¤U¦C¨BÆJ1»P¨BÆJ2ªº«ü¥Ü¶i¦æµ}ÄÀ¡C Å髹F30¤½¤ç¥H¤Wªº¯f¤H¡G¨Ï¥Î¸Ë¦³0.9%©Î0.45%´â¤Æ¶uª`®g¾¯100 mLªº¿éª`³U©Î¿éª`²~¡AµM«á¿í·Ó¤U¦C¨BÆJ1»P¨BÆJ2ªº«ü¥Ü¶i¦æµ}ÄÀ¡C ¡V ¨BÆJ1.¦Û¿éª`³U©Î¿éª`²~¤¤©â¥X»PActemra©Ò»Ý¾¯¶q¬Ûµ¥Åé¿nªº0.9%©Î0.45%´â¤Æ¶uª`®g¾¯¡C[½Ð°Ñ¨£¾¯¶q»Pµ¹ÃĤèªk(2.1)(2.2)(2.3)]¡C
¡V ¨BÆJ2.¦ÛActemra®ÃIJ~¤¤©â¥X©Ò»ÝÃľ¯Åé¿n¦A½wºC¥´¶i§t0.9%©Î0.45%´â¤Æ¶uª`®g¾¯ªº¿éª`³U©Î¿éª`²~¤¤¡C»´»´Ë¸mª`®g³U¨ÏÃľ¯²V¦X¡AÁקK²£¥Íªwªj¡C
¥H0.9%´â¤Æ¶uª`®g¾¯·»²G§¹¥þµ}ÄÀ«áªºActemra®¿éª`·»²G¥i¦b2-8 ¢XC (36-46¢XF)©Î«Ç·Å«O¦s³Ì¦h24¤p®É¡A¥BÀ³Á×¥ú¶J¦s¡C ¥H0.45%´â¤Æ¶uª`®g¾¯·»²G§¹¥þµ}ÄÀ«áªºActemra®¿éª`·»²G¥i¦b2-8 ¢XC (36-46¢XF)«O¦s³Ì¦h24¤p®É©Î«Ç·Å«O¦s³Ì¦h4¤p®É¡A¥BÀ³Á×¥ú¶J¦s¡C Actemra®¤£§t¨¾»G¾¯¡A¦]¦¹¦b¤p²~¤¤¥¼¥Î§¹ªºÃÄ«~§¡¤£¥i¦A¨Ï¥Î¡CƒÜ ¦bµ¹ÃÄ«e¡AÅýµ}ÄÀ«áªºÃľ¯¨ì¹F«Ç·Å¡C ³æ¦¸ÀR¯ßÂIºwµ¹ÃĮɶ¡À³¶W¹L60¤ÀÄÁ¥H¤W¡A¨Ã¥B¨Ï¥ÎÀR¯ß¿éª`³]³Æ¡C¤£¥iÀR¯ß±Àª`(bolus or push)¡C Actemra¤£¥i»P¨ä¥LÃĪ«¦@¥ÎÀR¯ß¿éª`ºÞ½u¡C¨Ã¨S¦³°w¹ïActemra®»P¨ä¥LÃĪ«¤@°_µ¹ÃĪºª«²z©Î¥Í¤Æ¬Û®e©Ê¶i¦æµû¦ô¬ã¨s¡C ƒÜ ª`®g§ë¤©¤§ÃĪ«¦bµ¹ÃÄ«e§¡À³¥Ø´úÀˬd¬O§_¦³²§ª«©ÎÅܦâ¡C¦pªGÆ[¹î¨ì²§ª«©ÎÅܦâ¡A¸ÓÃľ¯¤£¥i¨Ï¥Î¡C ƒÜ µ}ÄÀ«áªºActemra»Ppolypropylene¡Bpolyethylene¡Bpolyvinyl chloride§÷½èªº¿éª`³U¡A¥H¤Îpolypropylene¡Bpolyethylene©M¬Á¼þ§÷½èªº¿éª`²~¬O¥i¬Û®eªº¡C
|
¹L¶q³B²z |
|
¥Ø«eActemra¥ÎÃĹL¶qªº¬ÛÃö°O¿ý¤´¬Û·í¦³¡C¤@¥ó·N¥~¥ÎÃĹL¶qªº®×¨Ò¬°¤@¦ì¦hµo©Ê°©Åè½F¯f¤H±µ¨ü40 mg/kgªºÀR¯ßª`®gActemra®¾¯¶q¡A¦ý¥¼µo²{¤£¨}ÃĪ«¤ÏÀ³¡C°·±d§ÓÄ@¨ü¸ÕªÌ±µ¨ü³Ì°ª¹F28 mg/kgªº¾¯¶q«á¨Ã¥¼¥X²{ÄY«¤£¨}ÃĪ«¤ÏÀ³¡A¦ý5¦ì±µ¨ü28 mg/kg¾¯¶qªº¯f¤H¬Ò¥X²{¾¯¶q¨î©Ê¤§¶Ý¤¤©Ê¥Õ¦å²y§C¤U¯g¡C Y¥ÎÃĹL¶q®É«Øij¹ï¯f¤H¶i¦æ¤£¨}¤ÏÀ³¯gª¬ºÊ±±¡Cµo¥Í¤£¨}¤ÏÀ³ªº¯f¤HÀ³¬°¯gª¬±µ¨ü¾A·íªvÀø¡C
|
ÃÄ«~«O¦s¤è¦¡ |
|
Actemra¥²¶·Àx¦s©ó2¦Ü8ºC¡A½Ð¤Å§Ná«O¦s¡C ½Ð±NÃIJ~Àx¦s©óì¥]¸Ë¤¤¡AÁקK¥ú·Ó¡A©ó¨Ï¥Î®É¦A¶}±Ò¡C¨Ï¥Îª`®gÃľ¯«e¡AÀ³ºÉ¥i¯à¥H¦×²´Æ[¹îÃľ¯¬O§_¥X²{²§ª«©Îµo¥ÍÅܦâ¡C YÃľ¯Åܦâ¡B¥i¬Ý¨£¤£³z©úª«½è©Î¥X²{²§ª«¡A½Ð¤Å¨Ï¥Î¡C
|